Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panobacumab in P. aeruginosa HAP
NCT00851435Phase 2Completed
- Sponsor
- Kenta Biotech AG
- Start
- Feb 2008
- Primary completion
- Jul 2009
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of panobacumab in hospital-acquired pneumonia (HAP), sponsored by Kenta Biotech AG. Started Feb 2008; status: completed.
02
Drugs
panobacumab
03
Conditions
hospital-acquired pneumonia (HAP)
Beyond the preview
Go deeper on NCT00851435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00851435.